Aclaris' mixed PhIIb eczema data; Amgen licenses Xeris' tech; Bolden Tx secures funding
Aclaris Therapeutics reported mixed results for its JAK inhibitor in a Phase IIb eczema
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
